The treatment of chronic myeloid leukemia breaks through the dilemma of drug resistance, and the Handbook of Return to Society helps patients return to formal life

September 22 is the World Chronic Myeloid Leukemia Day, on this occasion, the 2022 International Chronic Myeloid Leukemia Day and the 9th China Chronic Myeloid Leukemia Patient Conference with the theme of "Continuing to Regenerate, Facing the Future" and the 9th China Chronic Myelogenous Leukemia Patient Conference were held in Beijing, Wuhan and

The conference shared and summarized the latest treatment progress and standardized medication of CML in China, and released the "Handbook for the Return of Adult Chronic Myeloid Leukemia Patients"

In the guest speech session, Professor Huang Xiaojun, Director of the Institute of Hematology and Disease of Peking University, pointed out: "With the emergence of the third generation of TKI drugs, CML treatment has moved towards the era of precision targeted therapy, more and more patients have benefited from new drugs and new treatment methods, and the survival time of more than 90% of CML patients has been able to approach normal people

During the conference, the forum "Care for Patients, Return to Society" was successfully held

In the process of communication, experts said that although drug-resistant patients do not account for a large proportion of CML patients, the treatment difficulty, economic burden and psychological burden of drug-resistant patients are heavier than ordinary patients

At the same time, the forum stressed the need to do a good job in popular science popularization, so that more people can correctly view CML

Tyrosine kinase inhibitors (TKI) are currently the preferred drug for the treatment of CML, with the wide application of TKI, the survival time of CML patients has approached the same age of normal people, CML has also been transformed from hematological tumor diseases to chronic diseases such as hypertension and diabetes, but there are still patients with drug resistance
.

BCR-ABL kinase region mutation is one of the important mechanisms leading to drug resistance after TKI treatment, with TKI resistance occurring in about 10% to 25% of CML patients [^2], of which T315I is a common mutation, accounting for about 20% of TKI clinical resistance, and resistance to both previous and second generations of TKI drugs ^[3].

In recent years, CML treatment methods and medication regimens have been constantly innovating
.

The follow-up monitoring and mutation detection of drug-resistant patients have realized the long-term standardized management of CML, which has effectively improved the treatment level and effectiveness
.

With the emergence of the third generation of TKI drug Orebatinib in China, the drug resistance dilemma of CML treatment has been fundamentally broken, and CML patients with T315I mutation have the latest drug choice
in clinical treatment.

In order to better serve CML patients and their families, improve the quality of life of CML patients, and pay attention to the return of CML patients, at the CML conference, the "Handbook for the Return of Adult Chronic Myelogenous Leukemia Patients" was officially released
.

The manual is divided into four parts: "Daily Nursing", "Employment", "Intimate Relationship" and "Mental Health", taking the practical problems faced by patients returning to society as the starting point, and providing positive and beneficial guidance
for CML patients with the help of clinicians, human resource managers, psychological counselors and other experts in various fields.

At the subsequent forum on "CML Drug Value and Social Value", Professor Zhang Gongli of Henan Provincial Cancer Hospital, Professor Xuan Jianwei of School of Pharmacy of Sun Yat-sen University, Professor Zou Ping of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Ms.
Xinyue of Social Work Fan and patient representatives had wonderful discussions
on topics such as the burden of CML patients, the changes in CML treatment brought by TKI, the clinical value of patient return, economic value and social value.

The forum pointed out that in the stage of standardized chronic disease management, the return to work to continue to shine fever is the choice
of most patients.

The return of CML patients to normal life not only means that they have a new life, but also plays an important role in medical research on CML
.

The emergence of TKI has put CML treatment on the right track and turned it into a controllable and curable chronic disease, and the social value created by the return of chronic disease patients to work and life cannot be ignored
.

On the day of the conference, the patient story documentary "The Power of Hope II" was also released, and a CML patient story online exhibition
was held.

Through the form of photos and videos, it shows the journey of CML patients, especially T315I mutation patients who originally had no medicine, from diagnosis, medical treatment, medication to return to normal life in society, and presents the efforts and gains
of CML patients in the process of fighting diseases.

In addition, many CML patients performed songs and dances on stage, showing their unique style and new life style
after returning to society.

Liu Zhengchen, Secretary-General of Beijing New Sunshine Charity Foundation, shared, "In the past 20 years, every patient and his family has witnessed the progress of medical science and technology, and with the improvement of treatment effect, many patients have returned to life and work, creating value
for society.

Over the years, Beijing New Sunshine Charity Foundation has united the forces of all walks of life to pay attention to the treatment progress of CML and the new life
of patients.

The New Sunshine Foundation will continue to help CML patients, and also look forward to more and more people being able to participate in the practical actions of CML patients and help CML patients create more social value
in their lives and work.

”

Reference source:

Hematology Branch of Chinese Medical Association.
Guidelines for the diagnosis and treatment of chronic myeloid leukemia in China (2020 edition)[J] .
Chinese Journal of Hematology,2020,41(05): 353-364.

2.
Chen C , Na X , Wu W E , et al.
The Clinical Characteristics and Efficacy of Chronic Myeloid Leukemia Patients with T315I Mutation[J].
Blood, 2018, 132(Suppl_1):5433-5433.
3.
Zhang Y , Swoboda D M , Grover A , et al.
T315I-mutated myeloid sarcoma[J].
Leukemia Research Reports, 2019, 12:100184.

3.
Zhang Y , Swoboda D M , Grover A , et al.
T315I-mutated myeloid sarcoma[J].
Leukemia Research Reports, 2019, 12:100184.

Poke "Read the original article" to see more